Teva gets EU antitrust objections over multiple sclerosis drug (update*)
Teva has received official antitrust charges from the European Commission, alleging that it illegally extended its dominance in multiple sclerosis treatment by gaming the patent system.Teva has received official antitrust charges...To view the full article, register now.
Already a subscriber? Click here to view full article